BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

CAPS Rating: 3 out of 5

A biopharmaceutical company that is utilizing its licensed, owned and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties.

Results 1 - 20 of 35 : 1 2 Next »

Recs

3
Member Avatar zzlangerhans (99.79) Submitted: 4/16/2015 2:02:37 PM : Outperform Start Price: $9.09 BDSI Score: -22.39

The failure of the phase III trial of Clonidine Gel for diabetic neuropathy was certainly disappointing, but I think the drop in share price has become excessive. BioDelivery now has a product on the market in Bunavail and the more commercially significant Belbuca in the regulatory process with a PDUFA on October 23. I'd expect a recovery as the PDUFA date grows closer.

Recs

0
Member Avatar TerryFool (81.09) Submitted: 2/13/2015 2:10:35 PM : Outperform Start Price: $9.80 BDSI Score: -28.95

BP 12 TP 22

Recs

0
Member Avatar Weidmans (39.73) Submitted: 10/21/2014 5:08:21 PM : Outperform Start Price: $16.41 BDSI Score: -61.49

Small Comapny, and lots of drugs in the works, just waiting for FDA Approval. Should see a steady rise over the next 2 years.

Recs

0
Member Avatar manirg (97.38) Submitted: 10/8/2014 9:48:52 AM : Outperform Start Price: $17.18 BDSI Score: -63.92

undervalued

Recs

1
Member Avatar herbslojewski (< 20) Submitted: 5/27/2014 5:21:28 PM : Outperform Start Price: $9.70 BDSI Score: -36.03

big things coming for bdsi, buy buy buy

Recs

1
Member Avatar SkepBioInvestor (95.25) Submitted: 1/20/2014 9:13:18 AM : Outperform Start Price: $6.73 BDSI Score: -10.67

Positive Phase 3 data of BEMA Buprenorphine

Recs

1
Member Avatar chris293 (70.11) Submitted: 9/17/2013 9:38:22 PM : Outperform Start Price: $5.41 BDSI Score: +4.06

Almost everyone picked this.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:22:00 PM : Underperform Start Price: $4.49 BDSI Score: -27.07

Short. Biotech, revs down 90%

Recs

1
Member Avatar Herbert7946 (< 20) Submitted: 7/9/2012 2:15:18 PM : Outperform Start Price: $5.00 BDSI Score: -16.77

huge profits on the way

Recs

1
Member Avatar D0min0 (< 20) Submitted: 10/5/2011 7:57:21 AM : Outperform Start Price: $0.99 BDSI Score: +473.00

Recently really beaten down by the failure of early phase 3 clinical trial results showing its pain drug BEMA Buprenorphine missed the primary target of its study, but Buprenorphine is already a Food and Drug Administration-approved drug for pain treatment. BDSI has $21 million in cash so a revised study is underway. Good company, well run, hit a bump in the road.

Recs

1
Member Avatar Closed4Good (< 20) Submitted: 6/25/2011 2:41:38 PM : Outperform Start Price: $3.45 BDSI Score: +31.55

A previously unproven company but with a practical piece of industry regulatory experience providing the perfect launch pad for a proven proprietary application process, poised to pick up the pace with partnerships and an particularly pleasing pipeline!

Recs

0
Member Avatar hslojewski (< 20) Submitted: 3/21/2011 5:46:47 PM : Outperform Start Price: $3.28 BDSI Score: +44.52

Lots of promise, could be a year off, maybe more, but good things will happen.

Recs

0
Member Avatar motleyjabberwock (< 20) Submitted: 3/3/2011 1:18:22 PM : Outperform Start Price: $3.52 BDSI Score: +35.04

1.6 PE, revenue growth of 675% over 3 years, and 290 ROE. Delicious fundamentals.

Recs

1
Member Avatar pageboy67 (43.64) Submitted: 12/8/2010 11:14:42 AM : Outperform Start Price: $2.80 BDSI Score: +69.44

Declining short interest in November will drive stock up.

Recs

0
Member Avatar sleeplessny (< 20) Submitted: 11/16/2010 11:32:02 PM : Outperform Start Price: $2.87 BDSI Score: +57.73

check out the balance sheet
it's a gold mine

Recs

0
Member Avatar ebitdat (< 20) Submitted: 9/23/2010 10:47:25 AM : Outperform Start Price: $2.80 BDSI Score: +55.95

Proven product and low valuation. Concerns about cash flow and liquidity are mitigated by proven partnership ability and able management

Recs

0
Member Avatar cibient (< 20) Submitted: 8/30/2010 2:36:07 AM : Outperform Start Price: $2.26 BDSI Score: +96.99

MFI screener. CEO bought shares on open market at prices higher than the low $2s. Basic valuation ratios look out of whack (P/E, etc.) and may reflect its biotech+microcap nature

Recs

0
Member Avatar 2gud2btrue (49.49) Submitted: 8/11/2010 12:25:21 PM : Outperform Start Price: $2.29 BDSI Score: +101.15

Target $6 - $9. Profit making Bio firm what else do you want.
11-08-10. Price $ 2.30

Recs

0
Member Avatar herbertslojewski (62.06) Submitted: 7/27/2010 7:34:55 PM : Outperform Start Price: $2.30 BDSI Score: +100.88

cuz I likes it

Recs

2
Member Avatar mogruith (74.54) Submitted: 6/18/2010 8:45:39 AM : Outperform Start Price: $2.73 BDSI Score: +59.74

Beaten down, recent insider buying, solid balance sheet.

Results 1 - 20 of 35 : 1 2 Next »

Featured Broker Partners


Advertisement